Capricor Therapeutics Faces Securities Litigation Over Clinical Data

The complaint centers on allegations that Capricor altered its statistical analysis plan for Deramiocel clinical data without prior FDA agreement before resubmitting its Biologics License Application. This shift reportedly masked significant risks regarding the drug's perceived effectiveness, leaving the company vulnerable to regulatory rejection. Shareholders claim these actions resulted in materially misleading public statements that inflated the stock's value until the reality of the FDA situation surfaced.

Brian Schall and David Schwartz of the Los Angeles-based firm are currently seeking lead plaintiffs to represent the class. While the case has not yet been certified, investors who suffered losses during the specified period may contact the firm to discuss potential recovery options. Participation in the lawsuit does not require an immediate appointment as lead plaintiff, and those who remain passive will continue to be classified as absent class members until the court formalizes the proceedings.